Literature DB >> 10203127

The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia.

C G Lyketsos1, E Galik, C Steele, M Steinberg, A Rosenblatt, A Warren, J M Sheppard, A Baker, J Brandt.   

Abstract

OBJECTIVE: Dementia is a serious public health problem. General medical comorbidity is common in dementia patients and critical to their care. However, little is known about medical comorbidity in these patients, and there are no straightforward bedside global rating scales for the seriousness of comorbid medical illness. This paper describes the development and measurement properties of the General Medical Health Rating (GHMR), a rapid global rating scale of medical comorbidity in dementia patients.
DESIGN: Interrater reliability, concurrent validity, and predictive validity of the GMHR are reported.
SETTING: An outpatient dementia clinic, assisted living, and nursing home. PARTICIPANTS: A total of 819 consecutive dementia clinic outpatients and 180 consecutive admissions to Copper Ridge, a long-term care residence for people with dementia, were included in the study.
RESULTS: GMHR was found to be highly reliable (weighted kappa = .91). Across all stages and types of dementia, GMHR ratings were correlated with number of comorbid medical conditions, number of medications being taken for comorbid conditions, and with activity of daily living impairment, even after adjustment for severity of dementia. GMHR ratings were also a strong predictor of falls and of mortality in long-term care residents after adjustment for age and severity of dementia.
CONCLUSION: GMHR is a reliable, valid, global bedside measure of severity of general medical comorbidity for patients with dementia that can be used for clinical and research purposes.

Entities:  

Mesh:

Year:  1999        PMID: 10203127     DOI: 10.1111/j.1532-5415.1999.tb07245.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  69 in total

1.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study.

Authors:  Matthew E Peters; Paul B Rosenberg; Martin Steinberg; JoAnn T Tschanz; Maria C Norton; Kathleen A Welsh-Bohmer; Kathleen M Hayden; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-05       Impact factor: 4.105

3.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

4.  Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Dingfen Han; Michelle M Mielke; Sarah N Forrester; JoAnn T Tschanz; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-06-12       Impact factor: 3.878

5.  Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.

Authors:  Michelle M Mielke; Jeannie-Marie Leoutsakos; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; JoAnn T Tschanz; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

6.  Head injury serum markers for assessing response to trauma: Design of the HeadSMART study.

Authors:  Matthew E Peters; Vani Rao; Kathleen T Bechtold; Durga Roy; Haris I Sair; Jeannie-Marie Leoutsakos; Ramon Diaz-Arrastia; Robert D Stevens; D Scott Batty; Hayley Falk; Christopher Fernandez; Uju Ofoche; Alexandra Vassila; Anna J Hall; Braden Anderson; Edward Bessman; Constantine G Lyketsos; Allen D Everett; Jennifer Van Eyk; Frederick K Korley
Journal:  Brain Inj       Date:  2017-01-31       Impact factor: 2.311

7.  The association between activity participation and time to discharge in the assisted living setting.

Authors:  Sarah K Tighe; Jeannie-Marie S Leoutsakos; Michelle C Carlson; Chiadi U Onyike; Quincy Samus; Alva Baker; Jason Brandt; Peter V Rabins; Lawrence Mayer; Adam Rosenblatt; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2008-06       Impact factor: 3.485

8.  Correlates of functional dependence among recently admitted assisted living residents with and without dementia.

Authors:  Quincy M Samus; Lawrence Mayer; Chiadi U Onyike; Jason Brandt; Alva Baker; Matthew McNabney; Peter V Rabins; Constantine G Lyketsos; Adam Rosenblatt
Journal:  J Am Med Dir Assoc       Date:  2009-06       Impact factor: 4.669

9.  Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.

Authors:  JoAnn T Tschanz; Chris D Corcoran; Sarah Schwartz; Katherine Treiber; Robert C Green; Maria C Norton; Michelle M Mielke; Kathleen Piercy; Martin Steinberg; Peter V Rabins; Jeanne-Marie Leoutsakos; Kathleen A Welsh-Bohmer; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2011-06       Impact factor: 4.105

10.  Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.

Authors:  Katherine A Treiber; Constantine G Lyketsos; Chris Corcoran; Martin Steinberg; Maria Norton; Robert C Green; Peter Rabins; David M Stein; Kathleen A Welsh-Bohmer; John C S Breitner; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2008-02-21       Impact factor: 3.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.